Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses
Articolo
Data di Pubblicazione:
2020
Citazione:
Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses / L. Cristina Gironi, G. Damiani, E. Zavattaro, A. Pacifico, P. Santus, P.D.M. Pigatto, O. Cremona, P. Savoia. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - (2020 Dec 22). [Epub ahead of print] [10.1111/dth.14694]
Abstract:
Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential antiviral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. A multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC was performed. About 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]) were enrolled. During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
COVID-19; SARS-Cov-2; doxycycline; drug re-proposal; inflammatory dermatoses; minocycline; tetracyclines
Elenco autori:
L. Cristina Gironi, G. Damiani, E. Zavattaro, A. Pacifico, P. Santus, P.D.M. Pigatto, O. Cremona, P. Savoia
Link alla scheda completa:
Link al Full Text: